Zosteriform scatris on the skin of the patient with acute myelogenous leukemia during the febrile neutropenia attack.

Skin lesions in patient with acute myeloid leukemia

Date: 29 June 2017

  • Zosteriform scatris on the skin of the patient with acute myelogenous leukemia during the febrile neutropenia attack.

  • Bullous lesions on the skin of the patient with acute myelogenous leukemia during the febrile neutropenia attack.

  • Zosteriform scatris with erythematous halo on the skin of the patient with acute myelogenous leukemia during the febrile neutropenia attack.

  • Histological findings of invasive cutaneous aspergillosis. Skin biopsy showing fungal hyphae accumulated in the dermiş.

  • Non-branching fungal hyphae and intensive neutrophil infiltration in the dermis. Fungal infiltration also seemed to invade the vessels.

Prev
Next

Images and abstract taken from Mert D et.al., Hematol Rep. 2017 Jun 1;9(2):6997. doi: 10.4081/hr.2017.6997. Invasive Aspergillosis with Disseminated Skin Involvement in a Patient with Acute Myeloid Leukemia: A Rare Case.

Invasive pulmonary aspergillosis is most commonly seen in immunocompromised patients. Besides, skin lesions may also develop due to invasive aspergillosis in those patients. A 49-year-old male patient was diagnosed with acute myeloid leukemia.

The patient developed bullous and zosteriform lesions on the skin after the 21st day of hospitalization. The skin biopsy showed hyphae. Disseminated skin aspergillosis was diagnosed to the patient.

Voricanazole treatment was initiated. The patient was discharged once the lesions started to disappear.

Copyright:

©Copyright D. Mert et al., 2017
Licensee PAGEPress, Italy
Hematology Reports 2017; 9:6997
doi:10.4081/hr.2017.6997

Notes: n/a

Images library

Showing 10 posts of 2574 posts found.

  • Title

    Legend

  • E1210 structure

    E1210

  • ABPA and mucoid impaction

    Patient YML ABPA and mucoid impaction Image 1, Patient YML ABPA and mucoid impaction Image 2

  • Patient JSG: Nicotine stained fingers in ABPA with bronchiectasis

    Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.

    Nicotine stained fingers - image 1, Nicotine stained fingers - image 2

  • T-2307

    The chemical structure of the novel arylamidine T-2307

    T2307

  • Laryngeal Aspergillosis, ptSA

    Laryngeal aspergillosis, probably related to inhaled corticosteroids.

    Image A., Image B., Image C., Image D.

  • VL-2397 (ASP2397)

    VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:

    • A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
    • Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
    • Activity against azole-resistant fungal species.
    • Low propensity for P450 drug-drug interactions.

    VL-2397 (ASP2397)

  • SCY-078 (MK-3118)

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.

    SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor

  • Biafungin acetate

    Biafungin acetate, a new echinocandin

    Biafungin acetate, a new echinocandin

  • Primary Aspergillus pneumonia

    Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010

    Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010, Pt DSM, Community acquired Aspergillus pneumonia 02/02/2010

  • Community acquired Aspergillus pneumonia